What is CHPA doing to address the methamphetamine problem?
The Consumer Healthcare Products Association (CHPA) is deeply concerned that safe and effective medicines manufactured by its member companies and purchased by millions of legitimate consumers to treat symptoms of colds, allergies, and asthma are being diverted to manufacture methamphetamine in small clandestine labs. DEA officials state that the majority of methamphetamine in the United States is either imported into this country as a finished drug or is produced in large super labs using bulk pseudoephedrine. While clandestine labs produce relatively small amounts of meth, they create hazardous problems for local law enforcement, communities, children, and the environment. CHPA feels strongly that the most effective way to significantly address methamphetamine production and abuse is through a multi-faceted approach that includes retail sales limits, placement restrictions, strong law enforcement, treatment, and demand-reduction initiatives that promote cooperation within communities
